Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 10Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 5Recurrence 3Prostatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lung Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Head and Neck Neoplasms 2Glioblastoma 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Thymoma 1Skin Neoplasms 1Salivary Gland Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Non Castrate Metastatic Prostate Cancer 1Neoplasms 1Nasopharyngeal Neoplasms 1

Interventions

Docetaxel 11Cisplatin 11Biopsy 7Radiotherapy 6Immunohistochemistry 6Carboplatin 6pembrolizumab 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Cetuximab 5Trastuzumab 4Paclitaxel 4Nivolumab 4Gemcitabine 4Chemotherapy, Adjuvant 4Capecitabine 4Surgical Procedures, Operative 3Specimen Handling 3Radiosurgery 3Ipilimumab 3Goserelin 3Fluorodeoxyglucose F18 3Everolimus 3Erlotinib Hydrochloride 3sacituzumab govitecan 2pyrotinib 2pertuzumab 2bicalutamide 2Taxes 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Salivary Gland Neoplasms × NVP-BKM120 × Clear all
NCT01816984 2021-10-05

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

University of Chicago

Phase 1/2 Completed
12 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡